Wee1 kinase downregulates the M-phase promoting factor, a complex of cdc2 and cyclin B kinase, that controls mitotic cell division. We isolated human wee1 kinase gene promoter and found that it contained one AP-1-binding motif in its promoter region (5 0 -CGAGTCA-3 0 ; À823/À817), through which wee1 kinase gene was directly transactivated by c-Fos/AP-1. In rheumatoid synovial cells, wee1 kinase was increased in conjunction with the increase of c-Fos/AP-1 and the substrate of wee1, cdc2, was phosphorylated. The amount of wee1 and c-Fos and the phosphorylation of cdc2 were decreased after treatment of the cells with an inhibitor of AP-1, curcumin. A significant proportion of cultured synovial cells of the patients with rheumatoid arthritis, but not those of osteoarthritis, shifted to a tetraploid (4C) state upon long-term culture. Thus, human wee1 kinase gene is directly transactivated by and increased in association with c-Fos/AP-1, and rheumatoid synovial cells overexpressing these genes go into aberrant mitosis.
Introduction
Cell cycle progression is known to be coordinated by a family of cyclin-dependent protein kinases (cdks) (Morgan, 1995) . However, little is known about the role of cyclin/cdk complexes in the regulation of cell cycle progression in rheumatoid arthritis (RA). There are, however, several lines of evidence suggesting that cell cycle progression may be significantly distorted in RA. First, the manner of the growth of rheumatoid synovial cells was 'tumor-like'. The cells with 'transforming' appearance containing abundant cytoplasm, large pale nuclei and prominent nucleoli with karyotypic alteration are typically found adjacent to the affected cartilage and bone of the joint in human RA and experimental animal models of arthritis (Shiozawa et al., 1983; Fassbender, 1984 Fassbender, , 1998 . Rheumatoid synoviocytes grow in disorganized monolayers and proliferate in an anchorage-independent manner (Yamanishi and Firestein, 2001) . Second, the transcription factors acting at the G1 phase of cell cycle including c-Fos/AP-1 (Trabant et al., 1992; Asahara et al., 1997) , Egr-1 (Aicher et al., 1994) , CREB (Wakisaka et al., 1998) and C/EBP (Pope et al., 1999) were increased, whereas the proportion of PCNA þ or Ki-67 þ (Jacobs et al., 1995; Schaser et al., 1996) cells was significantly decreased in rheumatoid synovium, suggesting that mitotic cell division may be halted in face of proliferation in RA.
c-fos gene is an immediate early gene expressed transiently in the G1 phase of cell cycle after receptor ligation (Piechaczyk and Blanchard, 1994) . The gene product c-Fos interacts with Jun family members to make an AP-1 heterodimer (Chinenov and Kerppola, 2001) . The c-Fos/AP-1 subsequently transactivates the genes containing the promoter consensus AP-1 motif TGAG/CTCA to progress the cell cycle (Shaulian and Karin, 2001) . We found that overexpression of c-fos gene not only caused synovial cellular overgrowth and arthritic joint destruction (Shiozawa et al., 1992 (Shiozawa et al., , 1997 Kuroki et al., 1993 Kuroki et al., , 1994 , but also induced skewed proliferation of T cells (Kawasaki et al., 1999 (Kawasaki et al., , 2001 , In mice, increased c-Fos/AP-1 directly transactivated the wee1 kinase gene to halt mitotic cell division by phosphorylating cdc2, in which wee1 kinase appeared to act as a break to inhibit transiently cellular G2/M transition, while c-Fos/AP-1 acted as an accelerator to drive cells to pass though G1/S (Kawasaki et al, 2001) .
In the present study, we studied human wee1 kinase in relation to the distortion of cell cycle progression, based on the finding that c-Fos/AP-1 was abnormally increased in RA (Trabant et al., 1992; Asahara et al., 1997) . We identified one AP-1-binding motif in the promoter region of human wee1 kinase gene, through which c-Fos/AP-1 directly transactivated the wee1 gene. We found that wee1 kinase was increased in conjunction with c-Fos/AP-1, substrate of wee1 kinase, cdc2, was phosphorylated, and cellular mitosis thus appeared halted in the face of proliferation in rheumatoid synovial cells. The result was discussed in relation to the genesis of 'tumor-like' characteristics in rheumatoid synovial cells.
Results

AP-1-binding site in human wee1 kinase promoter
We isolated the 5 0 -flanking region of the human wee1 gene from genomic DNA using nested PCR, starting with the primers for the human wee1 cDNA sequence (DDBJ/EMBL/GenBank AB019581). The isolated human 1140 bp fragment was confirmed to be the 5 0 -flanking region of wee1 gene by PCR, using an antisense primer from the known exon of the wee1 gene (DDBJ/EMBL/GenBank U10564). The human wee1 kinase promoter was found to contain one AP-1-binding motif (À823/À817, 5 0 -CGAGTCA-3 0 ) as well as binding motifs for other factors (Figure 1a , upper panel). The authentic transcription start site (TSS) was mapped by S1 nuclease protection mapping to B170 bp upstream of the translation start site (arrow head). A second potential TSS was found at B410 (Figure 1a , lower panel).
c-Fos/AP-1 directly transactivates human wee1 kinase Electrophoretic mobility shift assay (EMSA) using double-stranded AP-1 oligonucleotides from the human wee1 promoter showed that nuclear extracts of HeLa S3 cells obtained 8 or 24 h after stimulation with PMA bound to the AP-1-binding motif (Figure 1b , lanes 3 and 5). The bands were supershifted by anti-c-Fos Ab (Figure 1b , lanes 4 and 6). To test whether or not the binding of c-Fos/AP-1 onto the promoter region played a role in the transactivation of wee1 gene, site-directed mutations were introduced into the AP-1-binding motif of human wee1 promoter and the activity was determined by a transient reporter assay in the cells cotransfected with c-fos expression vectors. Efficient activation was obtained by using either the wild-type promoter (À823/À817; wild type), the promoter containing the consensus AP-1 motif (À823/À817, 5 0 -TGAGTCA-3 0 ; AP-1 cons) or the mutated promoter containing the c-Myc motif (À1084/À1079, 5 0 -CACG-GA-3 0 ; c-Myc mut) ( Figure 1c ). However, transactivation through the promoter containing a mutation in the AP-1 motif (À823/À817, 5 0 -GGAGTTG-3 0 ; AP-1 mut) or that containing mutations in both in AP-1 and c-Myc motifs (AP-1 and c-Myc mut) was inefficient ( Figure 1c) . We also observed that transactivation through the wildtype promoter was significantly decreased in the cells treated with curcumin, an inhibitor of AP-1 (Kaker and Roy, 1994; Hung et al., 1995) (Figure 1c) . Luciferase reporter assay of human wee1 promoter activity. The human wee1 promoter (À1140/À30) was subcloned into the pGL3-Enhancer vector to generate wild-type luciferase reporter plasmid. Site-directed mutations were introduced into AP-1 (À823/À817) or c-Myc (À1084/À1079) motifs of the wee1 promoter as follows: AP-1 mutant (AP-1 mut), CGAGTCA-CGAGTTG; AP-1 consensus (AP-1 cons), CGAGTCA-TGAGTCA; c-Myc mutant (c-Myc mut), CACGTG-CACGGA; AP-1&c-Myc mutant (AP-1&c-Myc mut), CGAGTCA-CGAGTTG and CACGTG-CACGGA. HeLa S3 cells were transfected with each vector and subsequently stimulated with 10 ng/ml PMA for 8 h. Cell lysates were assayed using a dual-luciferase reporter assay. Hela S3 cells-transfected wild-type vector were treated with 20 mm curcumin for 2 h, followed by stimulation with PMA for 8 h (wild type þ curcumin) Transactivation of wee1 kinase by c-Fos/AP-1 to RA H Kawasaki et al (Figure 2a, upper panel) . Both the mRNA expression of wee1 and c-fos was increased in rheumatoid synovial cells, as quantified by ABI7700 (data not shown). When rheumatoid synovial cells were treated with curcumin, an inhibitor of AP-1, the amounts of c-Fos and wee1 were significantly decreased (Figure 2b ), suggesting that wee1 kinase was increased in concert with and under the control of c-Fos/AP-1 in rheumatoid synovial cells.
Cell cycle progression of rheumatoid synovial cells
We next studied the expression of cell cycle regulators that were known to act primarily as the M-phase promoting factors (MPFs), in rheumatoid synovial cells (Figure 3a ). Cdc2 proteins were phosphorylated at Tyr15 in rheumatoid synovial cells, while the amount of cdc2 was similar between RA and OA. The amount of cyclinB and cdc25C were similar or somewhat increased in rheumatoid synovial cells, confirming that MPF activities were consistently depressed in rheumatoid synovial cells.
In such conditions, we naturally expect to find increased number of 4C cells, because the cells should have gone into aberrant mitosis when cdc2 was inactivated (Broek et al., 1991) . We found that cultured rheumatoid synovial adherent cells were dominantly at the G1 phase of cell cycle just after seeding, whereas after in vitro culture for 2 months, a significant proportion (11.872.3%) of the cells shifted to 4C (Figure 3b ). This shift was not found in cultured synovial cells in the OA model: the proportion of the cells in G2/M was at maximum 2.870.75% in OA.
Discussion
The result showed that c-Fos/AP-1 directly transactivated human wee1 gene through the AP-1-binding motif in wee1 promoter. Although there were additional putative binding motifs for c-Myc and Sp-1 in both human and mouse wee1 promoters, we found that the AP-1-binding motif was specifically required for the transactivation of wee1 kinase gene in human. Both c-Fos and wee1 kinase were basically increased in rheumatoid synovial cells, and they could be depressed by adding curcumin, a specific inhibitor of AP-1, indicating that wee1 kinase was increased in concert with and under the control of c-Fos/AP-1 in rheumatoid synovial cells.
Wee1 kinase inhibits the mitotic cell division by inactivating MPF, a complex of cdc2 kinase and cyclinB, that regulates cellular G2/M transition (Nurse, 1990) . MPF activity can be regulated positively by dephosphorylating cdc2 at Thr14 and Tyr15 (Norbury et al., 1991) , and negatively by phosphorylating cdc2 at Tyr15 (Gould and Nurse, 1989) . Dephosphorylation of Thr 14 and Tyr 15 is catalysed by cdc25 (Strausfeld et al., 1991) , and phosphorylation of Tyr15 is catalysed by wee1 kinase (Russell and Nurse, 1987) . It has recently been demonstrated that when MPF activity is continuously decreased, cells go into aberrant mitosis and remain in the 4C states (Broek et al., 1991; Zhang et al., 1996; Secchiero et al., 1998) . Previously, we found that under abnormally prolonged expression of c-fos gene, antigen-specific Th1 cells shifted to a state with tetraploid DNA content (4C) (Kawasaki et al., 2001) . It thus appears that when the expression of c-fos is Transactivation of wee1 kinase by c-Fos/AP-1 to RA H Kawasaki et al overly prolonged, as in the case of RA, wee1 kinase activity is also increased and its substrate cdc2 is inactivated by phosphorylation at Tyr15, and thus the cells go into aberrant mitosis.
While the manner and timing of the expression of c-fos appeared to differ between lymphoid cells and mesenchymal cells, in rheumatoid synovial cells overexpressing c-fos, we did find that MPF activity was depressed and the amount and the activity of wee1 kinase were specifically increased (Figure 3a) . We also found that a significant proportion of these cells indeed shifted from 2C to 4C, suggesting that mitotic cell division was halted in the face of increased proliferation by c-Fos/AP-1 in rheumatoid synovial cells. The finding is consistent with the previous notion that rheumatoid synovial cells behaved 'tumor-like' (Fassbender, 1984 (Fassbender, , 1998 . We found that rheumatoid synovial cells overexpressing c-Fos/AP-1 and wee1 kinase went into abberant mitosis, which may afford a tumor-like characteristic to rheumatoid synovial cells, since karyotypic alteration including ploidy changes is one of the characteristic features of tumors (Hartwell and Kastan, 1994) .
Materials and methods
Patients
Synovium was obtained during joint surgery from eight patients with RA (age: 63.477.5 years), who met the American College of Rheumatology (formerly, the American Rheumatism Association) diagnostic criteria (Arnett et al., 1988) , and seven patients with OA (age: 75.175.9 years). The profile of patients with RA was: functional class, 2.970.6; Steinbroker hand X-ray stage, 3.870.4; C-reactive protein, 5.372.4 mg/dl; white blood cell count, 8.572.0 Â 10 3 /mm 3 ; platelet count, 38.178.7 Â 10 4 /mm 3 ; erythrocyte sedimentation rate, 63.4728.6 mm/h; IgM rheumatoid factor, 150.97138.5 IU/ml; serum hemoglobin, 9.971.4 g/dl. All patients were treated with 4 mg (average) of prednisolone daily, three patients with 100 mg of d-penicillamine daily, one patient with 200 mg of salazosulfapyridine daily, one patient with 5 mg of methotrexate weekly and one patient with 100 mg of bucillamine daily.
Cell culture
Synovial cells were dispersed as described (Hino et al., 1995) , placed in a 10 cm dish (Asahi Techno Glass Corp, Tokyo, Japan), and cultured for 3 h in DMEM (Nissui Pharmaceutical Co., Ltd, Tokyo, Japan) containing 10% FCS (Biosciences Pty Ltd, Lome, Australia) supplemented with 50 U/ml penicillin and 50 mg/ml streptomycin (complete DMEM). Nonadherent cells were discarded, and the remaining adherent synovial cells were cultured for 3 days. For long-term culture, cells were maintained in complete DMEM for 2 months. Rheumatoid synovial cells were cultured in serum-free DMEM medium for 36 h to reduce the basal activity of transcription factors. The cells were then treated with 20 mm curcumin (BIOMOL Research Laboratories, Inc., Plymouth Meeting, PA, USA) for 4 h, followed by stimulation with 10% FCS (Mohan et al., 2000) . HeLa S3 cells (RCB0271, Riken Gene Bank, Tsukuba, Japan) were maintained in complete DMEM.
Western blot
Cells (2 Â 10 6 ) were suspended in 100 ml of lysis buffer (25 mm Tris-HCl, pH 6.8, 1% 2-ME, 5% glycerol, 1% SDS). After sonication, the protein fraction was obtained by centrifugation at 10 000 g for 10 min. Protein (10 mg) was separated by 7.5-15% SDS-PAGE and transferred to Immobion-P membrane (Millipore Corp., Bedford, MA, USA). The membrane was then incubated with rabbit IgG anti-c-Fos Ab (CalbiocemNovabiochem Corp., La Jolla, CA, USA), rabbit IgG antiwee1 Ab (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), rabbit IgG anti-cdc2 Ab (Santa Cruz) or rabbit IgG anti-phospho-Tyr15-cdc2 Ab (Cell Signaling Technology Inc., Beverly, MA, USA), rabbit IgG anti-cyclinB Ab (Santa Cruz) or rabbit IgG anti-cdc25C Ab (Santa Cruz), followed by reaction with the HRP-conjugated anti-rabbit IgG Ab and ECL enhanced chemiluminescence reagent (AmershamPharmacis Biotech, Buckinghamshire, UK).
Isolation of human wee1 promoter
The human wee1 promoter was isolated by nested PCR using the Genome Walker kit (Clontech laboratories, Inc., Palo Alto, CA, USA). The walking adaptor was ligated to the ends of genomic DNA fragments generated by digestion with EcoRI, ScaI, DraI, PvuII, or SspI. Primary PCR was conduced in a 25 ml reaction containing 2.5 mm MgCl 2 , 400 mm each dNTP, 1 Â LA buffer (Takara Shuzo Co., Ltd, Kyoto, Japan), 6% dimethyl sulfoxide, 3% glycerol, 1.25 U of LA Taq DNA polymerase (Takara), 50 ng of the adaptorligated genomic DNA (Clontech) and 200 nm each of adaptor sense (5 0 -GTAATACGACTCACTATAGGGC-3 0 ) and wee1-specific antisense (À1/ þ 29, 5 0 -CTACTCGAAG-GACTCGGCTGTCGTCGGCGG-3 0 ) primers. The PCR reaction was carried out at 981C for 20 s and 681C for 5 min for 35 cycles. Secondary PCR was conducted similarly in a 25 ml reaction containing 1 ml of the first PCR product, nested adaptor sense (5 0 -ACTATAGGGCACGCGTGGT-3 0 ) and nested wee1-specific antisense (À59/À30, 5 0 -CACAG-GACCTGGGGCGTCCGGAGGCGAGAG-3 0 ) primers. The PCR product, confirmed to contain the wee1 exons by sequencing, was subcloned into the pT7 Blue vector (Novagen Inc., Madison, WI, USA). Transcription factor-binding motifs on the wee1 promoter were investigated using online computer service (GenomeNet WWW server, http://www.genome.ad.jp). Reference þ 1 refers to the initiating ATG codon.
S1 nuclease mapping
Transcripts generated by T7 RNA polymerase from the pT7 vector were used as templates for mapping the native mRNA (MAXIscript Transcription Kits; Ambion Inc., Austin, TX, USA). To obtain a probe of uniform size, pT7 was treated with ApaI, before using as a template. The reaction (20 ml) containing 1 mg of linearized pT7, 2 ml of 10 Â transcription buffer, 1 ml of each 10 mm ATP, CTP and GTP, 0.5 ml of 10 mm UTP, 5 ml of 1 mm ChromaTides Fluorescein-12-UTP (Molecular Probes, Inc., Eugene, OR, USA) and 10 U of T7 RNA polymerase was carried out at 371C for 1 h. To this was added 2 U of DNase I in 20 ml of RNase-free water. Total RNA was isolated from HeLa S3 cells cultured with 10 ng/ml of PMA for 8 h. Labeled probe (20 ng) was hybridized with 10 mg of total RNA, followed by reaction with 50 U of S1 nuclease (Ambion). The protected RNA fragments were run on a denaturing 6% acrylamide gel and analysed in a 377 DNA sequencer (Perkin-Elmer Corp., Foster, CA, USA), followed by sizing on Genescan 2.0.2 software using Genescan-500 TAMRA as a size standard (Perkin-Elmer). ), cultured with or without 10 ng/ml PMA for 8 or 24 h, were suspended in 500 ml of hypotonic buffer (10 mm HEPES-KOH, pH 7.9, 1.5 mm MgCl 2 , 10 mm KCl, 0.5 mm EDTA, 0.5 mm DTT, 0.5 mm PMSF, 1 mm leupeptin and 1 mm aprotinin) on ice for 10 min. After adding 5 ml of 10% Nonidet P-40, cells were incubated on ice for 20 min and centrifugated at 2000 g for 3 min. Nuclear fractions were reacted with 200 ml of extraction buffer (20 mm HEPES-KOH, pH 7.9, 10% glycerol, 420 mm NaCl, 1.5 mm MgCl 2 , 0.2 mm EDTA, 0.5 mm DTT, 0.5 mm PMSF, 1 mm leupeptin and 1 mm aprotinin) on ice with agitation for 30 min. Supernatant, obtained after centrifugation at 15 000 g for 15 min, was stored in aliquots at À801C (nuclear extract). The nuclear extract (5 mg) was incubated for 30 min with 0.5 pmol of digoxigenin (DIG)-labeled double-stranded AP-1 oligonucleotide probe (À833/À809, 5 0 -TCCCCGAGGCCCGAGTCACCA-TTTCA-3 0 , 3 0 -AGGGGCTCCGGGCTCAGTGGTAAAGT-5 0 ) in a 20 ml reaction containing 20 mm HEPES-KOH, pH 7.9, 10% glycerol, 20 mm KCl, 0.5 mm EDTA, 0.5 mm DTT, 0.5 mm PMSF, 1 mg of BSA and 0.5 mg of poly (dI-dC) (Amersham). The probe was end-labeled with DIG-11-ddUTP (Roche Diabnostics Gmph, Mannheim, Germany). Supershift was performed by adding 1 mg of anti-c-Fos Ab. Samples were run on a 4% polyacrylamide gel using 1 Â TGE buffer (50 mm Tris, 380 mm glycine and 2 mm EDTA), and transferred to a positively charged nylon membrane (Roche). DIG-labeled oligonucleotides were visualized by incubation with alkaline phosphatase-labeled F(ab) 2 anti-DIG Ab, followed by chemiluminescence reaction with 100 mg/ml CSPD substrate (Tropix, Inc., Bedford, MA, USA).
Plasmids
The wee1 promoter (À1140/À30), subcloned into the pT7 Blue vector, was digested by SalI and BamHI. The SalI-BamHI fragment was cloned into the XhoI-BglII site of the pGL3-Enhancer vector (Promega, Madison, WI, USA) to generate a firefly luciferase reporter (wild-type luc). Site-directed mutations were introduced into the AP-1 motif (À823/ 
Transient transfection and luciferase assay
We transfected HeLaS3 cells (5 Â 10 6 ) with 20 mg of pGL3-Enhancer vector containing various wee1 promoters using a Bio-Rad electroporator (380 V, 950 mF) in 0.4 ml of Ca 2 þ -, Mg 2 þ -free phosphate-buffered saline. After overnight culture in complete DMEM, cells were then treated with 20 mm of curcumin for 2 h, followed by stimulation with PMA (10 ng/ml). As an internal control for transfection efficiency, 2 mg of pRL-TK (Promega) containing herpes simplex virus thymidine kinase promoter in the upstream of Renilla luciferase was cotransfected. The cells were lysed in 100 ml of Passive lysis buffer (Promega). Lysates (20 ml) were analysed for luciferase activity using the Dual-luciferase Reporter Assay (Promega) in a Luminoskan (Labsystems, Tokyo, Japan). Activities of both firefly and Renilla luciferases were measured sequentially, and the activity of firefly luciferase was normalized with respect to that of Renilla luciferase.
Cell cycle assay
Cell cycle progression was assessed by measuring cellular DNA content of the cell by flow cytometry. DNA was stained by Cycle TEST PLUS (Becton Dickinson, San Jose, CA, USA). Cells (1 Â 10 6 ) were incubated with trypsin at r.t. for 10 min, followed by trypsin inhibitor and RNase A at r.t. for 10 min, followed by staining with propidium iodide and spermine tetrahydrochloride. Fluorescence intensity was measured in a FACSCalibur and analysed using FACScomp and ModeFit software (Becton Dikinson).
Abbreviations DIG, digoxigenin; EMSA, electrophoretic mobility shift assay; MPF, M-phase promoting factor; OA, osteoarthritis; PCNA, proliferating cell nuclear antigen; PMA, phorbol 12-myristate 13-acetate; RA, rheumatoid arthritis; TSS, transcription start sit.
